Interestingly, consistent with the network pharmacological analysis, our findings confirmed that oral administration of TPG downregulated serum IL-1, IL-2, IL-4, and IL-6 levels in PD rats, markers of peripheral inflammation. Here, IL6 is linked to Parkinson disease.